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Mutations activating KRAS underlie many forms of
cancer, but are refractory to therapeutic targeting.
Here,wedevelopPoloppin, an inhibitorofprotein-pro-
tein interactions via the Polo-box domain (PBD) of the
mitotic Polo-like kinases (PLKs), in monotherapeutic
and combination strategies to target mutant KRAS.
Poloppin engages its targets in biochemical and
cellular assays, triggering mitotic arrest with defec-
tive chromosome congression. Poloppin kills cells ex-
pressingmutant KRAS, selectively enhancing death in
mitosis. PLK1 or PLK4 depletion recapitulates these
cellular effects, as does PBD overexpression, corrob-
oratingPoloppin’smechanismof action. Anoptimized
analog with favorable pharmacokinetics, Poloppin-II,
is effective against KRAS-expressing cancer xeno-
grafts. Poloppin resistance develops less readily
than to an ATP-competitive PLK1 inhibitor; moreover,
cross-sensitivity persists. Poloppin sensitizes mutant
KRAS-expressing cells to clinical inhibitors of c-MET,
opening opportunities for combination therapy. Our
findings exemplify the utility of smallmoleculesmodu-
lating the protein-protein interactions of PLKs to ther-
apeutically target mutant KRAS-expressing cancers.
INTRODUCTION
Human Polo-like kinase 1 (PLK1) regulates multiple events that
lead to accurate chromosome segregation during cell divisionCell Chemical Biology 24, 1017–1028, Aug
This is an open access article und(reviewed in Bruinsma et al., 2012). It comprises an N-terminal
kinase catalytic domain, and a C-terminal segment with tan-
dem motifs that form the Polo-box domain (PBD). The PBD en-
gages pSer/pThr phosphopeptide substrates to recruit PLK1 to
mitotic structures (Elia et al., 2003a), direct PLK1 kinase activity
(Kang et al., 2006), and mediate reaction-diffusion mechanisms
for centrosome assembly (Mahen et al., 2011). Homologous
PBDs, in which key residues implicated in phosphopeptide sub-
strate recognition are conserved, also occur in the related human
Polo-like kinases PLK2, PLK3, and PLK4 (reviewed in Archam-
bault and Glover, 2009).
PLK1’s essential role in mitosis, and its dysregulation in
several different forms of human cancer, has prompted efforts
to create small-molecule inhibitors (reviewed in Liu, 2015).
Potent ATP-competitive small-molecule inhibitors of PLK1 ki-
nase activity are in clinical development (reviewed in Gjertsen
and Schoffski, 2015). Moreover, compounds that inhibit PBD
binding to phosphopeptide substrates are reported to induce
mitotic arrest and apoptosis in cancer cell lines at micromolar
concentrations (Reindl et al., 2008; Scharow et al., 2015; Wata-
nabe et al., 2009; Yuan et al., 2011); but several have recently
been identified as non-specific protein alkylators (Archambault
and Normandin, 2017).
Mutations activating the small GTP-binding protein KRAS,
which occur frequently in human cancers, have proven largely
refractory to therapeutic targeting (reviewed in McCormick,
2015). Inhibitors unique to the G12C KRAS mutant have been
described (Ostrem et al., 2013), as have inhibitors of an essential
interaction between KRAS and the prenyl-binding protein, PDEd
(Chandra et al., 2012; Zimmermann et al., 2013). An RNAi screen
for factors whose depletion inhibits the growth of mutant
KRAS G12D-expressing cancer cell lines identified PLK1 and
components of the APC/C ubiquitin-conjugating holoenzymeust 17, 2017 ª 2017 The Authors. Published by Elsevier Ltd. 1017
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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C Figure 1. Poloppin Is a Drug-like Inhibitor of
Phosphopeptide Binding by PLK1 PBD
(A) Structure of Poloppin.
(B) Poloppin competitively inhibits the binding of
a TAMRA-labeled substrate peptide to the PLK1
PBD in an FP assay.
(C) Isothermal titration calorimetry of Poloppin
binding to the PBD domain of PLK1.
(D) Poloppin stabilizes PLK1 in a cellular thermal
shift assay (CeTSA) in HeLa cell lysates.
(E) ITDRFCETSA at a constant temperature of 67
C in
HeLa lysates treated with Poloppin.
(F) Poloppin induces dose-dependent mitotic
arrest.
(G) Representative images of U2OS cells treated
with Poloppin. Green, tubulin; blue, DNA; red, ki-
netochores. Scale bars, 15 mm.
(H) Quantification of Poloppin-induced mitotic phe-
notypes in U2OS cells. The frequency of observed
mitotic phenotypes is displayed.
Data represent the mean of three independent
experiments ± SEM. See also Figure S1.(Luo et al., 2009). Genetic modulation of the pathway linking
PLK1 to APC/C activation curtailed the proliferation of mutant
KRAS G12D-expressing cancer cells, while ATP-competitive
PLK1 inhibitors suppressed their growth as xenografts.
Here, we identify compounds that modulate protein-protein
interactions of the structurally related PLK kinases via the PBD
domain, and demonstrate their utility in strategies to target
mutant KRAS. Poloppin (Polo protein-protein interaction inhibi-
tor) kills cells expressing mutant KRAS in two-dimensional or
organoid cultures. An optimized analog (Poloppin-II) is effec-
tive against KRAS-expressing cancer xenografts after systemic
oral administration. Notably, Poloppin sensitivity persists in can-1018 Cell Chemical Biology 24, 1017–1028, August 17, 2017cer cells resistant to an ATP-competitive
PLK1 inhibitor, and Poloppin sensitizes
mutant KRAS-expressing cells to clinically
used inhibitors of the MET tyrosine kinase,
opening opportunities for combination
therapy.
RESULTS
A Drug-like Inhibitor of
Phosphopeptide Binding by
PLK1 PBD
We screened a diversity library of 120,000
drug-like molecules (Huggins et al., 2011),
using a fluorescence polarization (FP)
assay (Figures S1A–S1C), to identify com-
pounds that inhibit the binding of the
human PLK1 PBD with a tetramethyl-
6-carboxy-rhodamine (TAMRA)-labeled
PLK1 PBD consensus binding phospho-
peptide. Close analogs of the primary hits
were selected by Tanimoto similarity using
extended-connectivity fingerprints (Xia
et al., 2004), before experimental valida-
tion. Poloppin (Figure 1A), a 438 Da com-pound identified in this way, is lipophilic but soluble at up to
1 mM in 5% DMSO, contains no obvious chemical toxicophores
or reactive groups, and thereforewas regarded as a suitable start-
ing point for development. Poloppin exhibits a half maximal inhib-
itory concentration (IC50) of 26.9 mM by FP (Figure 1B), while
isothermal titration calorimetry reveals that it directly binds to the
PLK1 PBD with a Kd of 29.5 mM (Figure 1C).
Poloppin Engages PLK1 to Trigger Mitotic Arrest with
Non-congressed Chromosomes
We tested whether Poloppin engages cellular PLK1 using the
recently described cellular thermal shift assay (CeTSA). CeTSA
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Figure 2. Poloppin Preferentially Kills Cells
Expressing Mutant KRAS in Two-Dimen-
sional and Organoid Cultures
(A) Cell viability in SW48 isogenic parental or
KRASG12D cell lines.
(B) Cell viability in MEFs from either a KRAS wild-
type, p53R172H (KRAS WT p53 MUT), or a mutant
KRASG12D, p53R172H (KRASMUT p53MUT) strain.
(C) Viability in murine pancreatic organoids from
either a KRAS wild-type, p53R172H (KRAS WT p53
MUT) or mutant KRASG12D, p53R172H (KRAS MUT
p53 MUT 1 and 2) strain.
Data represent the mean of three independent
experiments ± SEM unless otherwise stated.detects cellular target engagement via changes in the thermal
stability of the drug-bound target, but does not track directly
with the potency of compounds in biochemical or phenotypic
assays (Jafari et al., 2014; Martinez Molina et al., 2013; Martinez
Molina and Nordlund, 2016). PLK1 protein exhibits increased
thermal stability following treatment with a fixed dose of
1 mM Poloppin compared with control (Figure 1D). Moreover,
exposure of cell lysates at a constant 67C to increasing doses
of Poloppin, using isothermal dose-response fingerprint
(ITDRF)-CeTSA, demonstrates that cellular PLK1 is stabilized
at >40 mM (Figure 1E). Together, these results provide evidence
that Poloppin engages PLK1 in the cellular milieu.
Further evidence comes from the cellular phenotypes induced
by Poloppin. Poloppin triggers dose-dependent mitotic arrest
in human cell lines (Figure 1F), inducing multiple anomalies
in mitosis. At a 12.5 mM concentration, <5% of cells exhibit
normal metaphase chromosome alignment, instead arresting
with bipolar or disordered spindles and non-congressed chro-
mosomes (Figures 1H and 1G). Poloppin-induced mitotic arrest
with non-congressed chromosomes is dissimilar from that
induced by ATP-competitive PLK1 inhibitors, which typicallyCell Chemical Biolsuppress bipolar spindle formation (Gil-
martin et al., 2009; Hanisch et al., 2006;
Lenart et al., 2007).
Collectively, these findings suggest
that an early requirement for PLK1 ki-
nase activity during mitotic progression
is distinct from the role of substrate
engagement by the PBD (Hanisch et al.,
2006). Indeed, Poloppin elicits mitotic
phenotypes at relatively low concentra-
tions compared with its apparent activity
in biochemical assays, consistent with
the notion that the compound competi-
tively inhibits PBD binding to function-
ally relevant substrates present at low
cellular abundance, rather than acting
as an ATP-competitive catalytic inhibitor.
Poloppin Kills Cells Expressing
Mutant KRAS in Two-Dimensional
and Organoid Cultures
Mutant KRAS expression sensitizes cells
to genetic or pharmacologic modulationof PLK1 (Luo et al., 2009) by 2-fold over controls. Similarly,
SW48cells expressingKRASG12Dexhibit2-foldgreater sensi-
tivity to Poloppin than isogenic controls (Figure 2A), as doprimary
murine embryonic fibroblasts (MEFs) genetically engineered to
acutely expressmutantKRASG12Dwhen treatedwith 4-hydroxy
tamoxifen (Figure 2B). Poloppin has a greater (4- to 5-fold;
average, 4.7-fold) inhibitory effect on the growth of pancreatic or-
ganoids formed by pancreatic epithelial cells derived from mice
genetically engineered to express mutant KRAS G12D in the
pancreas (KRAS MUT p53 MUT 1 and 2) compared with KRAS
wild-type (KRAS WT p53 MUT) controls (Figure 2C).
Poloppin Exerts its Cellular Effects via the PBDDomains
of PLKs
Poloppin does not bind (Figure S1D) to the kinase catalytic
domains of either PLK1 or its homologs, PLK2, PLK3, or PLK4,
using the DiscoverX KinomeScan assay (Fabian et al., 2005;
Karaman et al., 2008). No significant binding was observed
to 51 other protein kinases bearing structural or functional
similarity to the Polo-like kinases. However, Poloppin inhibits
phosphopeptide substrate engagement to the PBD of PLK1ogy 24, 1017–1028, August 17, 2017 1019
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Figure 3. Poloppin Exerts Its Cellular Effects via the PBD Domains of PLKs
(A) Thermal stability assay for PLK1–4 using NanoLuc fusion proteins.
(B) Mitotic index assay in HeLa Flp-In T-REx cells.
(C) Cell viability in the SW48 isogenic parental or KRASG12D cell lines following depletion of PLKs using indicated siRNAs.
(D) Quantitation of mitotic phenotypes. HeLa cells engineered to overexpress PLK1-PBD upon addition of doxycycline were treated with compounds at EC50
concentrations or with doxycycline (PBD O/E) for 16 hr. Mitotic phenotypes were quantified by immunofluorescence imaging. Green, tubulin; blue, DNA; red,
kinetochores. Scale bars, 15 mm.
(E) Cell viability of HeLa cells expressing doxycycline-inducible PLK1-PBD, with or without constitutively overexpressed mCherry-KRAS G12D.
Data represent the mean of three independent experiments ± SEM. See also Figure S2.(Figure 1B; IC50 = 29 mM), and with 3-fold less activity (Fig-
ure S1E; IC50 = 88 mM), to the closely related PBD domain of
human PLK2when tested by FP. Since PLK1–4 all harbor homol-
ogous PBD domains (van de Weerdt et al., 2008), we tested
whether Poloppin might exert its cellular effects via the inhibition
of PLK2, PLK3, or PLK4, besides PLK1.
In cells transiently expressing fusions between PLK1–4 and
the reporter Nanoluciferase (NanoLuc) (Hall et al., 2012; Masser
et al., 2016), Poloppin at 100 mM increases the thermal stability
of all four NanoLuc-PLK fusion proteins (Figure 3A), but not an
irrelevant NanoLuc-p38aMAPK fusion protein (Figure S2). These
results suggest that Poloppin engages PLK1–4.
We therefore testedwhether the selective depletion of PLK1–4
using RNAi could recapitulate Poloppin-induced phenotypes.
Depletion of PLK1 or PLK4 but not PLK2 or PLK3 triggers mitotic
arrest (Figure 3B). Moreover, PLK1 or PLK4 depletion preferen-1020 Cell Chemical Biology 24, 1017–1028, August 17, 2017tially decreased the survival of SW48 cells expressing KRAS
G12D over that of isogenic control cells (Figure 3C), whereas
PLK2 or PLK3 depletion had no such effect. Thus, our findings
suggest that PLK1 and PLK4 inhibition underlies the activity of
Poloppin in triggering mitotic arrest, and in preferentially killing
cancer cells that express mutant oncogenic KRAS.
Next, we tested whether inducible overexpression of the PLK1
PBD in cells, which is expected to mimic the effects of Poloppin
by competitively inhibiting substrate engagement to the PBD
domains, could recapitulate these phenotypic effects. Indeed,
cells induced to overexpress the PBD by treatment with doxycy-
cline (Figure 3D) undergo a characteristic metaphase arrest with
non-congressed chromosomes, which is typical of the effect
induced by Poloppin (Figures 1G and 1H). Inducible PBD expres-
sion also preferentially reduces in a dose-dependent manner the
viability of cells co-expressing mutant KRAS, over that of the
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Figure 4. Poloppin Sensitizes Cells Ex-
pressing Mutant KRAS to Death in Mitosis
(A and B) Live-cell imaging of (A) parental HeLa
cells and (B) HeLa cells expressing KRASG12D
treated with DMSO or with Poloppin at their GI50
dose. Each horizontal bar represents the fate of a
single cell visualized by serial time-lapse imaging.
Colors indicate the different cell fates.
(C) Quantitation of the percentage and type of cell
death.
(D) Graph showing time spent in mitosis.
***p < 0.001. Error bars represent the 95% confi-
dence interval from the mean.parental cells (Figure 3E), by 2-fold, as expected. Thus, collec-
tively, our findings provide genetic evidence to corroborate that
the cellular effects of Poloppin aremediated via the PBDdomain.
Poloppin Sensitizes Mutant KRAS-Expressing Cells to
Death in Mitosis
Using live-cell imaging to track the fate of single wild-type HeLa
cells exposed to Poloppin (Figure 4), we find that Poloppin
exposure prolongs mitosis from an average of 60 to 100 min
(compare black segments in Figures 4A and 4B; tabulated in Fig-
ure 4D), and increases the frequency of aneuploid divisions to
38% (purple segments and yellow segments), compared with
4% after DMSO treatment. Typically, Poloppin-treated wild-
type cells exit mitosis to form binucleate or anucleate daughters,
which undergo death during the subsequent interphase (yellow
segments).
By contrast, Poloppin treatment sensitizes mutant KRAS-ex-
pressing HeLa cells to death inmitosis. Induction of a chromoso-
mally integrated, doxycycline-inducible KRAS G12D transgeneCell Chemical Bioincreases the time taken for mitosis
from 100 to 200 min (compare black
segments in Figure 4A versus 4B; tabu-
lated in Figure 4D), consistent with the
notion that mutant KRAS dysregulates
mitotic progression as recently reported
(Perera and Venkitaraman, 2016). How-
ever, when mutant KRAS-expressing
HeLa cells are exposed to Poloppin (Fig-
ure 4B), there is also a sharp increase
in the frequency of death in mitosis (red
segments) when compared with DMSO-
exposed controls (Figure 4C, 3% versus
36%). Collectively, these results suggest
that Poloppin preferentially sensitizes
mutant KRAS-expressing cells, but not
controls, to death in mitosis.
An Optimized Poloppin Analog Is
Effective In Vivo against Mutant
KRAS-Expressing Xenografts
An optimized synthetic analog, Polop-
pin-II (Figure 5A), is soluble at up
to 100 mM in 5% DMSO, and exhibits
no binding at 5 mM to the kinase catalytic
domains of PLK1–4, or to 51 other relatedkinases using the DiscoverX KinomeScreen assay (Figure S3A).
It induces mitotic arrest with non-congressed chromosomes
similar to that induced by Poloppin (Figure 5B). Poloppin-II ex-
hibits a half maximal effective concentration of 61 nM in a cellular
assay for mitotic arrest compared with 14.6 mM for Poloppin,
whereas a structurally related analog of Poloppin-II (PB114) is
inactive (Figure 5B). Poloppin-II engages PLK1 and PLK4, as de-
tected using NanoLuc fusion proteins, whereas PB114 is less
active (Figure S3C). Poloppin-II sensitizes cells expressing
mutant KRAS in two-dimensional or organoid cultures by
approximately 5-fold (Figures 5C and 5D).
Despite its potency in cellular assays, Poloppin-II competi-
tively inhibits substrate binding to the PLK1 PBD with an
apparent IC50 of only 41 mM using an FP assay, less than that
of Poloppin, and is also active against PLK2 PDB with an IC50
of 105 mM (Figure S3D). Although the hydrophobicity of the
compounds has precluded validation of their binding modes
using X-ray crystallography, two possible explanations may ac-
count for the disconnect between their apparent potencies inlogy 24, 1017–1028, August 17, 2017 1021
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Figure 5. The Optimized Analog Poloppin-II Is Effective by Systemic Oral Administration In Vivo Against Mutant KRAS-Expressing
Xenografts
(A) Synthetic chemistry route from Poloppin to Poloppin-II. The EC50 value of each analog in a cellular assay for mitotic arrest is given below its designation, with
the maximum percentage of mitotic cells in brackets.
(B) Mitotic index assay in HeLa cells treated for 16 hr with Poloppin, Poloppin-II, or the structurally related analog, PB114.
(C) Cell viability in KRAS wild-type murine pancreatic organoids (KRAS WT p53 MUT), or organoids expressing KRAS G12D (KRAS MUT p53 MUT).
(D) Cell viability in SW48 parental and KRAS G12D isogenic cell lines at 72 hr. Data represent the mean of three independent experiments ± SEM.
(E) Mass spectrometric analysis of changes in phosphopeptide abundance induced by Poloppin-II versus Nocodazole or the ATP-competitive PLK1 inhibitor,
Volasertib. Pairwise comparisons of the relative abundance of phosphopeptides detected in this analysis are plotted logarithmically to the base 2 (top panels).
Green dots indicate phosphopeptides that contain the PLK1 phosphorylation consensusmotifs. The boxed, yellow-shaded area in the bottom left-hand quadrant
marks phosphopeptides that exhibit a R2-fold reduction in abundance in both conditions. The tables below each dot plot show the total number of
(legend continued on next page)
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biochemical versus cellular assays. First, switching from an acid
(Poloppin) to an amine (Poloppin-II) may alter cell permeability
or retention. Second, recent data (Zhu et al., 2016) suggest
that the PBD domain assumes ordered dimeric conformations
in the cellular milieu to regulate PLK1 activity, raising the possi-
bility that the relevant target conformer in cells is distinct from
the recombinant PBD proteins used in the FP assay. Neverthe-
less, we cannot exclude entirely the possibility that Poloppin-II
acts via targets additional to the PLK PBD.
To further corroborate Poloppin-II’s cellular mechanism of
action, we used stable isotope labeling using amino acids in
culture coupled to mass spectrometry (see STAR Methods) to
compare the patterns of changes induced in the human phos-
phoproteome after mitotic arrest triggered by Poloppin-II with
the spindle poison, Nocodazole, or with the ATP-competitive
PLK1 inhibitor, Volasertib (Figure 5E). The abundance of 95
phosphopeptides is decreased R2-fold after both Poloppin-II
and Nocodazole exposure (yellow box, left-hand plot), of which
only one (1.05%) contains the PLK1 phosphorylation consensus
motifs (D/E)-X-(S/T)-(F), (F)-(D/E)-X-(S/T)-(F), and (F)-X-(D/E)-X-
(S/T)-(F), where F is a hydrophobic residue (Oppermann et al.,
2012). By contrast, 238 phosphopeptides decrease byR2-fold
after both Poloppin-II and Volasertib exposure (yellow box,
right-hand plot), of which 42 (17.65%) contain consensus PLK1
motifs. These findings suggest that Volasertib and Poloppin-II,
but not Nocodazole, preferentially inhibit the phosphorylation
of a common set of cellular proteins containing consensusmotifs
for PLK1-dependent phosphorylation. Since phosphopeptide
engagement via the PBD is a critical step that directs PLK kinase
activity to its substrates (Elia et al., 2003a, 2003b), these data
strengthen the evidence supporting Poloppin-II’s mechanism
of action in cells.
Poloppin-II is inactive against the hERG ion channel, and
is stable in human (CLint = 10 mL/min/million cells; T1/2 =
136 min) and mouse (CLint = 18 mL/min/million cells; T1/2 =
77 min) hepatocytes. Upon oral administration in mice (Fig-
ure S3E), Poloppin-II maintains an in vivo plasma concentra-
tion >100 nM for >24 hr following a single dose of 10 mg/kg.
Oral bioavailability exceeds 90%, with a half-life of 15 hr, calcu-
lated clearance of 17 mL/min/kg and a volume of distribution
of 23 L/kg. These favorable attributes prompted us to test the
efficacy of Poloppin-II in an in vivo xenograft model using the
mutant KRAS G13D-expressing colorectal cancer cell line,
HCT116 (Figure 5F). Poloppin-II at 50 mg/kg (Figure S3F) was
well tolerated during the study, with no adverse health obser-
vations or recorded weight loss (Figure S3G). At this dose,
Poloppin-II reduced the growth of xenografted tumors in a
statistically significant manner (Figures 5F and S3H). Xeno-
grafts exposed to Poloppin-II exhibit increased levels of phos-
pho-Ser10 histone H3 expression within 24 hr compared with
vehicle-treated controls (Figure S3I), providing a pharmaco-
dynamic marker of xenograft exposure, and linking reduced
tumor growth to mitotic arrest.phosphopeptides, the number of PLK1 motif-containing phosphopeptides, and th
defined by (log2) abundance values.
(F) Tumor progression in a xenograft model of HCT116 cells expressing KRASG1
indicate mean ± SD.
See also Figure S3.Poloppin Resistance Develops Less Readily than to an
ATP-Competitive PLK1 Inhibitor
Mutant KRAS-expressing HCT116 colorectal carcinoma cells
have previously been used to investigate resistance to PLK1 in-
hibition by the ATP-competitive PLK1 inhibitor, BI2536 (Wacker
et al., 2012). When treated with 5 times the half maximal growth
inhibition (GI50) concentrations of either Poloppin or BI2536 (Fig-
ure 6A), BI2536-resistant, but not Poloppin-resistant, colonies
are readily observed (Figure 6B). BI2536-resistant cells harbor
the known resistance mutation, PLK1 R136G (Wacker et al.,
2012) (Figure S4A). Mutations affecting PLK2 or PLK3 were not
detected. Interestingly, BI2536-resistant cells retain sensitivity
to Poloppin (Figure 6C).
Poloppin Sensitizes Mutant KRAS-Expressing Cells to
Clinically Used Inhibitors of the c-MET Tyrosine Kinase
The proto-oncogene c-MET, a bona fide therapeutic target in
human malignancies, including pancreatic cancer (reviewed
in Cecchi et al., 2012), is upregulated in KRAS-mutant SW48
cells versus isogenic controls (Figure 7A). c-MET depletion using
small interfering RNA (siRNA) (Figure S5A) selectively increased
sensitization to Poloppin at the GI25 dose in mutant KRAS-
expressing SW48 cells but not their parental counterparts (Fig-
ure 7B; charcoal and red bars). This effect does not occur
with Poloppin alone (black and blue bars). In addition, several
different cancer cell lines bearing mutant oncogenic KRAS
were sensitized by 2- to 4-fold to Poloppin after depletion of
c-MET using siRNA (Figure S5B).
We tested several c-MET inhibitors, including Crizotinib
(Xalkori), an FDA-approved compound (Rodig and Shapiro,
2010), for late-stage non-small-cell lung cancers that express
the abnormal anaplastic lymphoma kinase. SW48 KRAS-G12D
cells are approximately 7-fold more sensitive to Crizotinib in
the presence of Poloppin compared with SW48 parental cells
(Figures 7C and 7D). A similar but greater effect is also observed
in murine pancreatic organoids expressing mutant oncogenic
Kras compared with controls (Figure 7E). In addition, several
different KRAS-mutant cell lines were sensitized to Crizotinib
in the presence of Poloppin (Table S1). Similar effects were
apparent using two alternative MET inhibitors, Foretinib (Qian
et al., 2009) or Tivatinib (Yap et al., 2011), currently in clinical
development (Figure S5C). RNAi depletion of PLK1, but not other
PLKs, sensitized mutant KRAS-expressing cells to Foretinib,
whereas depletion of PLK1–4 induced sensitization to Crizotinib,
supporting the proposed mechanism of action (Figure S5D).
Poloppin and Crizotinib are synergistic at doses below both
their respective GI50 values for cell killing in Panc-1 cells, using
the BLISS independence method, which assumes that the
agents may act via independent mechanisms (Figure 7F). In a
similar manner, Poloppin-II also sensitizes Panc-1 cells to Crizo-
tinib at doses below their respective GI50 for cell killing, acting in
a synergistic manner (Figure 7G). These results indicate that
combining the c-MET inhibitor, Crizotinib, with either Poloppine percentage of PLK1 motif-containing phosphopeptides in nine different bins
3D after systemic treatment via oral administration with Poloppin-II. Error bars
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(C) Viability of drug-sensitive parental HCT116 cells (HCT116 WT) and BI 2536-resistant clones (HCT116 BI 2536-Res. Clones) treated with BI2536 or Poloppin.
(D) The GI50 dose for each compound is shown for each cell line.
Data represent the mean of three independent experiments ± SEM. See also Figure S4.or Poloppin-II arrests the growth ofmutant KRAS-bearing cancer
cells with greater efficacy than when the compounds are used
independently, and suggest that c-MET inhibition acts synergis-
tically with inhibition of the PLK PBD.
DISCUSSION
Here, we report the development of Poloppin and Poloppin-II
as chemical leads that inhibit phosphopeptide binding by
the PBD motifs conserved in the human Polo-like kinases,
PLK1–4. Neither compound shares chemical features with
several previously reported PBD inhibitors recently reported to
be non-specific protein alkylators (Archambault and Normandin,
2017). Moreover, both compounds lack reactive groups likely to
induce irreversible inhibition, and do not detectably interact with
a panel of 51 structurally or functionally related protein kinases.
Notably, Poloppin and Poloppin-II trigger mitotic arrest
with non-congressed chromosomes consistent with blockade
of the essential functions of PLK1 PBD during cell division,
and distinct from the monopolar spindle phenotype induced by
ATP-competitive PLK1 inhibitors. Both compounds also kill can-
cer cells expressing mutant oncogenic KRAS. Several lines of1024 Cell Chemical Biology 24, 1017–1028, August 17, 2017evidence speak to themechanism bywhich Poloppin and Polop-
pin-II elicit these cellular effects.
Both compounds inhibit phosphopeptide substrate binding to
the homologous PBD domains of PLK1 and PLK2 in biochemical
assays, and engage PLK1–4 in the cellular milieu when tested by
cellular thermal shift. Depletion using RNAi of PLK1 or PLK4 but
not PLK2 or PLK3 can recapitulate mitotic arrest and the killing
of mutant KRAS-expressing cells. These findings collectively
suggest that the Poloppins selectively engage the PBD1–4 target
domains, and, furthermore, that suppression of PLK1 and PLK4
underlies their key cellular effects in triggering mitotic arrest, and
in killing cancer cells that express mutant oncogenic KRAS.
Overexpression of the PLK1 PBD elicits similar cellular effects,
further supporting the proposed mechanism of action.
Whereas Poloppin-II is highly potent in inducing these cellular
phenotypes, it is perplexingly less active in biochemical assays,
raising the possibility that the compound acts via cellular targets
additional to the Polo-like kinases. However, like its parental
compound Poloppin, Poloppin-II does not bind detectably to a
DiscoverX KinomeScan panel, comprising 51 human protein ki-
nases that exhibit structural or functional similarity with PLK1.
Moreover, mass spectrometric analyses indicate that Volasertib
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(legend continued on next page)
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(an ATP-competitive PLK1 inhibitor) and Poloppin-II, but not
Nocodazole (a mitotic spindle poison), preferentially decrease
the phosphorylation of cellular proteins containing consensus
motifs for PLK1-dependent phosphorylation. These observa-
tions discount the likelihood that Poloppin-II exerts its observed
cellular effects via additional targets.
Mutant KRAS expression is proposed to trigger abnormalities
in progression throughmitosis (‘‘mitotic stress’’) that render can-
cer cells sensitive to PLK1 inhibition (Luo et al., 2009). Consistent
with this proposal, induction of mutant KRAS G12D expression
in HeLa cells suffices to delay the completion of mitosis (Perera
and Venkitaraman, 2016), although it does not by itself signifi-
cantly increase cell death. Similarly, Poloppin treatment of both
wild-type and mutant KRAS G12D-expressing cells also delays
mitosis; however, Poloppin treatment preferentially sensitizes
mutant KRAS but not wild-type cells to death in mitosis. Thus,
our results suggest that the inhibition of substrate recognition
by the PBD of PLKs cooperates with mutant oncogenic KRAS
expression to trigger death in mitosis.
The in vivo bioavailability and favorable pharmacokinetic
properties of Poloppin-II, when coupled to its low nanomolar
potency in cellular assays, enable for the first time an analysis
of tolerability and efficacy by systemic oral administration in an
in vivo xenograft model, representing an advance over previ-
ously reported PBD inhibitors suitable only for intra-tumor injec-
tion (Yuan et al., 2011). Poloppin-II has a modest, 4- to 5-fold,
selectivity for the killing of cells expressing mutant KRAS over
wild-type cells. Nevertheless, the compound is relatively well
tolerated in mice, and exhibits in vivo activity against mutant
KRAS-expressing xenografts, with concomitant mitotic arrest
within the tumor, suggesting that its therapeutic index for the
treatment of mutant KRAS-expressing cancers may exceed
that observed in cellular assays.
Cancer therapy using ATP-competitive kinase inhibitors
frequently triggers drug resistance via point mutations in the
active site (Van den Bossche et al., 2016; Wacker et al., 2012).
Interestingly, resistance to Poloppin is undetectable in mutant
KRAS-expressing HCT116 cells, which, however, readily ac-
quire resistance to an ATP-competitive PLK1 inhibitor, BI2536,
through their mutator phenotype. This finding may reflect that
Poloppin inhibits both PLK1 and PLK4 to kill mutant KRAS-
expressing cells. BI2536-resistant cells remain sensitive to
Poloppin, suggesting the potential utility of PBD-inhibitory com-
pounds in overcoming drug resistance to ATP-competitive PLK1
inhibitors.
Notably, Poloppin and Poloppin-II sensitize mutant KRAS-
expressing cancer cells to inhibition of the tyrosine kinase re-
ceptor c-MET. Since c-MET inhibitors are already in clinical
development for the treatment of cancers of the lung, pancreas,
or other organs in which KRAS mutations are also frequent, our
findings suggest further interesting opportunities for combina-
tion therapy.(F and G) An analysis of synergy between Crizotinib in combination with Poloppin (
graphs show the percentage change in cell viability after treatment with the in
checkerboard titration indicating dose ranges for synergy (indigo) or antagonism
doses of Crizotinib with Poloppin (F) or Crizotinib with Poloppin-II (G), compared
Results are typical of at least three independent experiments. Data represent the
also Figure S5 and Table S1.
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Mutations activating the KRAS oncogene drive human can-
cers affecting the pancreas, lung, colon, and other tissues.
We report here that Poloppin and Poloppin-II, compounds
that target the protein-protein interactions of human Polo-
like kinases, suppress the growth of KRAS-mutant cancer
cells as single agents, or in combination with c-MET inhibi-
tors. The cellular phenotypes evoked by Poloppins speak
to amechanism of action that exploits mitotic vulnerabilities
triggered by mutant KRAS expression, via the interruption
of phosphopeptide substrate recognition by the Polo-box
domains of PLK1 or PLK4. Structure-activity relationships
defined by the features of Poloppin-II, a potent analog with
favorable pharmacokinetics active in vivo against KRAS-
mutant xenografts, indicate avenues for further develop-
ment. Poloppin is less susceptible to in vitro drug resistance
compared with an ATP-competitive PLK1 inhibitor, and
retains activity against cells resistant to the ATP-competi-
tive compound, suggesting methods to combat drug resis-
tance. Poloppin and Poloppin-II act synergistically with
Crizotinib, a clinically used inhibitor of the c-MET receptor,
against mutant KRAS-expressing cancer cells, revealing
an approach for combination therapy. Thus, we implicate
the protein-protein interactions of PLK1 and PLK4 in
the maintenance of mutant KRAS-expressing cancers, and
illustrate the use of compounds that block these interac-
tions in single-agent or combination therapies. Our findings
endorse the future potential of strategies to target substrate
recognition by human protein kinases for drug development.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
anti- PLK1 Invitrogen 33-1700
anti-phospho-histone H3 (Ser10) Abcam ab5176
Hoechst 33342 Invitrogen H3570
anti-GAPDH Santa Cruz sc137179
anti-alpha tubulin Santa Cruz sc32293
anti-CREST Europa 90C-CS1058
anti-c-MET Cell Signalling Technology 8198
Chemicals, Peptides, and Recombinant Proteins
Poloppin this study
Poloppin II this study
PLK1-PBD345-603 this study
PLK2-PBD356-681 this study
TAMRA-MAGPMQTS(pThreonine)PKNGAKK Designer Bioscience
BI 2536 SelleckChem S1109
Nocodazole Sigma M1404
Superscript III Life Technologies 18080044
Rnase H digest New England Biolabs M0297S
Amplitaq Gold Polymerase Applied Biosystems N8080241
Acetic acid VWR 20104.334
Sulforhodamine B sodium salt Sigma S1402-5G
Trizma base Sigma T6066
Trichloroacetic acid solution Sigma T0699-100ml
Critical Commercial Assays
Rneasy Mini Kit Qiagen 74104
Nextera XT Kit Cambridge Genomic Services
CellTitre Glo 3D assay Promega
Experimental Models: Cell Lines
HeLa Parental (Flp-In T-Rex) Tighe et al., 2004
HeLa KRAS G12D Perera and Venkitaraman, 2016
HeLa PLK1-PBD326-603 this study
HeLa ATCC
U2OS ATCC
Panc-1 ATCC
HPAF II ATCC
DLD-1 ATCC
SW1116 ATCC
HT29 ATCC
Panc 02.03 ATCC
Panc 05.04 ATCC
SW48 Parental (KRAS WT) Horizon Discovery
SW48 KRAS G12D Horizon Discovery
Experimental Models: Organisms/Strains
Mouse: LSL-Trp53R172H/+ Hingorani et al., 2005; Boj et al., 2015
Mouse: LSL-KrasG12D/+ Hingorani et al., 2005; Boj et al., 2015
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REAGENT or RESOURCE SOURCE IDENTIFIER
Mouse: Pdx-1-Cre Hingorani et al., 2005; Boj et al., 2015
Athymic nude mice, male Harlan (UK)
Oligonucleotides
Primer: PLK1F 5’-TTGTAACGTTCCCAGCGC
Primer: PLK1R 5’-GGCACACTGCAGACATGGC
Primer: PLK2F 5’-TGCTAGTCGGCACCAGAGG
Primer: PLK2R 5’-TTCGTACCACCACATGTCCA
Primer: PLK3F 5’-CGCAGCGTAGCAAATCCAG
Primer: PLK3R 5’-AAAGCTGGTCCCTGATTCCC
HS_Met_SG QuantiTect Primer Assay Qiagen QT00023408
HS_PLK1_SG QuantiTect Primer Assay Qiagen QT00049749
HS_PLK2_SG QuantiTect Primer Assay Qiagen QT00049406
HS_PLK3_SG QuantiTect Primer Assay Qiagen QT00025207
HS_PLK4_SG QuantiTect Primer Assay Qiagen QT00029967
HS_Actin_SG QuantiTect Primer Assay Qiagen QT01680476
siRNA: c-Met-AACACCCATCCAGAATGTCAT Qiagen
siRNA: c-Met-AAGCCAATTTATCAGGAGGTG Qiagen
siRNA: c-Met-AAGTATCAGCTTCCCAACTTC Qiagen
siRNA: Plk1-CAACGGCAGCGTGCAGATCAA Qiagen
siRNA: Plk2-SMARTpool Dharmacon
siRNA: Plk3-SMARTpool Dharmacon
siRNA: Plk4-AAGGACTTGGTCTTACAACTA QiagenCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to the LeadContact, Ashok R. Venkitaraman (arv22@
mrc-cu.cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
Doxycycline (DOX)-inducible HeLa KRASG12D and PLK1-PBD326-603 cells were generated using the Flp-In T-REx system (Life Tech-
nologies) (Tighe et al., 2004). The human KrasG12D or PLK1-PBD326-603 transgene was subcloned into a modified pcDNA5/FRT/TO
vector containing a single amino-terminalMyc tag, followedbyco-transfectionwith aplasmidencoding Flp recombinase (pOG44) into
HeLa FRT/TO cells (a kind gift from Stephen Taylor, University of Manchester). Stable integrants were then selected with 200 ug/ml
hygromycin (Roche) and 4 ug/ml blasticidin (Invivogen). Transgene expression was induced by treatment with 100 ng/ml doxycycline
(Sigma). HeLa, U2OS, Panc-1, HPAF II, DLD-1, SW1116, HT29, Panc 02.03 and Panc 05.04, cells were obtained from the American
TypeCulture Collection (ATCC). HeLa, U2OS andPanc-1were cultured inDMEMcontaining 10% (v/v) fetal bovine serum (FBS). Panc
02.03 and Panc 05.04 were cultured in RPMI medium containing 15% FBS and 10 units/ml Insulin. DLD-1, SW1116, HT29 were
cultured in RPMI medium containing 10% FBS. The SW48 isogenic cell lines (KRAS wild-type and KRASG12D) were purchased
from Horizon Discovery and cultured in RPMI medium containing 10% FBS. All cells were maintained at 37C with 5% CO2.
Primary Cell Cultures
KrasWT mouse embryonic fibroblasts (MEFs) were derived from conditional LSL-Trp53R172H/+ embryos. LSL-Trp53R172H/+, LSL-
KrasG12D/+ (Hingorani et al., 2005) strains were interbred to obtain LSL-KrasG12D/+, LSL-Trp53R172H/+ KrasG12D embryos for MEF
preparation. Briefly, MEFs were derived from E13.5 embryos after decapitation and evisceration. Finely minced tissue was passed
through a 16-G needle two or three times before dissociated cells were cultured in DMEM with 10% FBS. Cre-mediated recombi-
nation to activate the KrasG12D allele was induced via addition of 500nM 4-OH Tamoxifen to the culture media overnight.
Organoid cultures were prepared from the pancreas of LSL-Trp53R172H/+, Pdx-1-Cre (for KrasWT organoids) or LSL-Trp53R172H/+,
LSL-KrasG12D/+, Pdx-1-Cre (for KrasG12D organoids KPC3760 and KPC26684) strains (Hingorani et al., 2005). Pancreatic ducts were
manually picked after tissue mincing and overnight enzymatic digestion with 0.012% (w/v) collagenase XI (Sigma) and 0.012% (w/v)
dispase (GIBCO) in DMEM media containing 1% FBS (GIBCO), before seeding in growth-factor-reduced (GFR) Matrigel (BD) (Boj
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In Vivo Animal Studies
Male athymic mice were purchased from Harlan (UK) and acclimatised for 7 days prior to study commencement. Animals were
housed in IVC cages (5 per cage) with individual mice identified by tail marking. All animals were allowed free access to a standard
certified commercial diet and sanitised water during the study. The holding room was maintained under standard conditions:
20-24C, 40-70% humidity and a 12h light/dark cycle. All experiments were performed under approved ethical and procedural
guidelines.
METHOD DETAILS
Engineering of PLK1-PBD and PLK2-PBD Fusions
A region of the human PLK1 cDNA sequence (residues 345–603) or human PLK2 cDNA sequence (residues 356-681) was amplified
by PCR and cloned into a pGEX-6P1 vector (Invitrogen, Carlsbad, CA) to generate recombinant protein in C41 strain E. coli (Garcia-
Alvarez et al., 2006). Bacteria were disrupted using an Emulsiflex c5 homogenizer (Avestin) and lysates were passed onto a gluta-
thione S-transferase (GST)-Sepharose column in the presence of 50mM Hepes pH 7.5, 200mM NaCl, 1 mM EDTA, 1mM EGTA
and 1mM DTT. Bound fractions were cleaved on column at 4C overnight with PreScission protease (GE healthcare). Purified frac-
tions were polished by gel chromatography using a Sephadex G25 (GE healthcare) column, collected and concentrated. Fractions
were tested by Western blotting using PLK1 antibody (Invitrogen 33-1700) to validate protein purification.
Fluorescence Polarisation Assay
Final concentrations of assay components used in binding assays were as follows: TAMRA-labelled consensus PLK1 PBD binding
phosphopeptide, 5-TAMRA-MAGPMQS(pThreonine)PLMGAKK-acid 10nM; PLK1 PBD (aa345-603) 84nM (2.5ng/ml). Assays were
carried out in PBS (pH 7.4) plus 0.03% tween. DMSO controls were run alongside all experimental compounds and% inhibition nor-
malised to these controls. Compounds were titrated 2 fold from a top concentration of 250mM giving a maximum final concentration
of DMSO in the assay of 0.25%; however the assay can tolerate DMSO up to 5%. Compound and PBD protein were incubated
together at 22C for 1 hour prior to addition of the TAMRA labelled binding phosphopeptide. The total assay volume per well was
45ml. All experiments were performed in NBS black 384-well microtiter plates (Corning). Fluorescence Polarisation (FP) was read us-
ing a BMG PheraStar plate reader with a 540/590/590nm FP module and unbound 10nm TAMRA-labelled peptide set to a FP value
of 35mP.
For FP assays using PLK2 PBD (aa356-681), the same procedure was applied except that TAMRA-MAGPMQTS(pThreonine)
PKNGAKK was used as the consensus binding phosphopeptide.
For PLK1 PBD FP high-throughput screen the assay components were as above, compounds were screened at an approximate
final concentration of 125mM and final DMSO concentration of 1%. Appropriate volumes of TAMRA-labelled phosphopeptide and
Plk1 PBD at 3X final concentration were made up in PBS + 0.1% tween and PBS + 1mM DTT respectively and placed in reservoirs
on the Beckman Coulter Biomek FXp AutomatedWorkstation deck in the positions indicated by the scheduling software. Compound
dilution plates, black 384 well NBS assay plates and tip racks were loaded into the Cytomat as indicated by the scheduling software.
The appropriate Fluorescence Polarisation program was initiated on the BMG PheraStar plate reader and was manually set using an
assay plate and 10nm TAMRA-labelled peptide to a FP value of 35mP. All labware was checked to ensure that it is correctly posi-
tioned before the scheduling software was enabled and the HTS run was initialised. Test compounds were diluted to 3X final con-
centration in the dilution plates. 15ml of diluted compoundwas added into eachwell of the assay plate followed by 15ml of PBD protein
and 15ml of TAMRA-phosphopeptide. Plates were incubated at room temperature for between 20 and 40min on the robot’s deck or in
the Cytomat before the Fluorescence Polarisation was read using the BMGPheraStar plate reader. Test compoundswere assayed in
triplicate. Mean % inhibition normalised to DMSO control (1%) was calculated for each compound.
Isothermal Titration Calorimetry
In all titrations, PBDaa345-603 protein was used at 25 mM and buffered in HEPES (50 mM, pH 7.4), NaCl (200 mM), and DTT (1mM).
Protein was diluted into buffer with DMSO at 5% (v/v). Poloppin was prepared by diluting from DMSO stock into the same buffer
containing DMSO at 5% (v/v). Great care was taken tomatch the concentration of DMSO in the ligand and protein samples as closely
as possible. In a typical experiment, protein (25 mM) was loaded in the sample cell, and a total of 20 injections of 8mL were made at
2min intervals from a 200 mL syringe rotating at 1000 rpmand loadedwith ligand solution (0.5mM). In all titrations, an initial injection of
2 mL ligand was made, and these data were discarded during data analysis. The thermodynamic parameters were obtained by fitting
the data to a single-site binding model with a stoichiometry of 1. ITC experiments were performed at 20 C with a MicroCal ITC200
instrument, and all data were analysed with the software implemented in Origin (version 7) (Scott et al., 2015).
Mitotic Index Assay
Cells were plated at 10 000/well in 96-well plates and incubated overnight. The following day compound stocks in DMSOwere diluted
in medium then added to cells with a maximum final DMSO concentration on cells of 0.2%. Cells were incubated with compound for
24 h then fixed in 3.7% formaldeyde. Cells were permeabilised with 0.1% Triton X-100 then incubated with anti-phospho-histone H3
(Ser10) antibody (Abcam ab5176). The cells were washed with PBS then incubated with AlexaFluor 488 labelled goat anti-rabbit IgG
(Invitrogen A11034) in the presence of 4ug/ml Hoechst 33342 (Invitrogen H3570). Cells were washed in PBS then imaged on anCell Chemical Biology 24, 1017–1028.e1–e7, August 17, 2017 e3
Arrayscan VTi HCS instrument (Thermo Fisher) using the Target Activation V4Bioapplication. A user-defined thresholdwas applied to
identify mitotic cells based on the intensity of phospho-histone H3 staining.
Cellular Thermal Shift Assay (CeTSA)
Two million HeLa cells were assessed for viability using Trypan blue and aliquoted into PCR tubes for lysate preparation and CeTSA.
Aggregation temperature (Tagg) was determined for PLK1 PBD with a Biorad Tetrad gradient maker, using a final concentration
of 1mM or 0.5mM for Poloppin or Poloppin-II, respectively, in 5% DMSO (Jafari et al., 2014). Samples were assessed using PLK1
antibodies (Invitrogen 33-1700) and GAPDH (Santa Cruz sc137179) and Li-Cor antibody (926-32252). Quantification was done
with Odyssey Li-Cor technology.
NanoLuc Thermal Shift Assay
HeLa cells were transfected with plasmids encoding NanoLuc fused to the N-termini of full-length human PLK1, PLK2, PLK3, PLK4 or
p38a MAPK. Twenty-four h after transfection, the thermal stability of the fusion proteins was tested using a modified version of the
assay protocol supplied by Promega. Briefly, cells were harvested by tyrpsinisation and centrifugation, counted, and resuspended to
200,000 cells/ml in 3mls of serum-free OptiMEM media. Cells were then permeabilised using with 50ug/ml digitonin in DMSO for
5 min and incubated with test compounds at 100uM, plus protease inhibitor cocktail (Promega G6521), in a final concentration of
5% DMSO for 1 h at 37C. After incubation, 100 ml/well of cells were aliquoted into a 96-well, thin-walled PCR plate and then heated
for 3minutes using a pre-warmedMJ Tetrad DNAEngine set to run a temperature gradient of 42 to 66C. The plates were then cooled
to room temperature for 10 min, and then 80ml of each sample was transferred to a white-walled 96-well Nunc plate before
NanoBRET NanoGlo Substrate diluted in Opti-MEM was added. NanoLuc enzyme activity was read out within 10 min using a
BMG Clariostar plate reader.
DiscoverX KINOMEscan Assay
A panel of 55 proteins (comprising 51 human kinases structurally or functionally related to the PLKs, plus the kinase catalytic domains
of PLK1, PLK2, PLK3 and PLK4) were selected for testing by DiscoverX using the KINOMEscan assay platform. Compounds were
supplied as 40x DMSO stocks and were tested at a final concentration of 50mM for Poloppin and 5mM for Poloppin-II. Binding inter-
actions were reported as percentage of control where lower numbers indicate stronger binding. A cut-off of <35% was applied to
report significant binding.
Immunofluorescence
Cells were plated on glass coverslips and incubated overnight. Cells were treated with compound diluted in medium for 24hrs. Me-
dium was then removed and cells fixed in 20mM PIPES pH8, 20mM HEPES pH8, 5mM EGTA, 2mM MgCl, 0.2% Triton X-100 and
3.7% formaldehyde. Cells were washed in PBS containing 0.1% Tween-20 then incubated with anti-alpha tubulin antibody (Santa
Cruz sc-32293) and anti-CREST antibody (Europa 90C-CS1058). Cells were washed then incubated with Alexa Fluor 568 labelled
goat anti-mouse IgG (Invitrogen A11031) or Alexa Fluor 633 labelled goat anti-mouse IgG (Invitrogen A21052) and Alexa Fluor 488
goat anti-human IgG (Invitrogen A11013). Cells were washed and then mounted on glass slides in Vectashield mounting medium
containing DAPI.
Western Blotting
Total protein was isolated by directly lysing the cells in non-denaturing lysis buffer (20mMTris HCl pH 8, 137mMNaCl, 10%glycerol,
1% Nonidet P-40 (NP-40), 2 mM EDTA). Protein lysates were resolved on SDS-PAGE, transferred onto a Immobilon-P, PVDF mem-
brane (Millipore), and probed with: Plk1 antibody (Invitrogen 33-1700), c-MET antibody (Cell Signalling Technology 8198). Secondary
HRP-conjugated antibodies were used and the signal was detected using an Amershamenhanced chemiluminescence system (ECL,
GE Healthcare).
Viability Assays
SW48 Parental, SW48 G12D, Panc-1, HPAF-II, Panc 02.03 and Panc 05.04 cell lines were seeded overnight at 5000 cells per well in a
96 well plate in recommendedmedia (ATCC). Compounds were added the following day and viability was measured at 72h using the
sulforhodamine B (SRB) colorimetric assay as follows. Cells were fixed by replacing media with 1% v/v Trichloroacetic Acid (TCA)
(Sigma-Aldrich) at 4C and incubated for 1h also at 4C. Wells were washed thoroughly with copious amounts of deionised water
before staining with Sulforhodamine B (SRB) (Sigma-Aldrich) solution (0.057% w/v in 1% v/v Acetic Acid (VWR)) for 30 min. Stain
was aspirated and wells washed with several changes of 1% v/v Acetic Acid until unbound stain was removed, before air-drying.
Bound stain was solubilized with 100ml / well 10mM Tris (pH 8.0) (Trizma Base (121.1) Sigma-Aldrich) with agitation for 10 min. Fluo-
rescence intensity was recorded at Ex540nm / Em590nm using a BMG Pherastar Plus plate reader (Vichai and Kirtikara, 2006).
Pancreatic organoids were extracted and cultured as detailed above (Boj et al., 2015). In brief, pancreatic organoids were seeded
at 600 cells per well in a 96 well plate and allowed to grow for 7 days with media replenishment on the 3rd day. Full-grown organoids
were then treated with compounds for 72h and viability determined using CellTitre Glo 3D assay (Promega). For viability assays with
c-MET siRNA, cells were reverse transfected in a 6 cm dish using Dharmafect 1 (GE Dharmacon) per manufacturer’s instructions. On
the following day, cells were trypsinised and plated onto 96 well plates or 6 well plates. The 96 well plates were treated with a dosee4 Cell Chemical Biology 24, 1017–1028.e1–e7, August 17, 2017
range of compounds or DMSO, and viability was determined via SRB colorimetric assay. Cells in the 6 well plates were collected at
the end of experiment to corroborate knockdown of c-MET by Western blotting.
PBD Overexpression in KRASG12D Cells
HeLa cells engineered to inducibly overexpress Plk1-PBD (HeLaPBD-326) were transfected with mCherry tagged KRAS G12D
(HeLaPBD-326 mCherry KRAS G12D). After selection in Puromycin (0.3ug/ml) for one month, the mCherry positive population
was sorted by FACS and alongside the parental cells subjected to a viability assay. HeLaPBD-326 and HeLaPBD-326 mCherry
KRAS G12D cells were seeded at 2.5x103 cells/well in 96-well plates. The following day cells were treated with a titration of doxy-
cycline. At the end of 72h incubation period SRB colorimetric assay was performed to assess viability.
Live Cell Imaging
Five x104 cells were seeded on each well of 4-well coverglass Lab-Tek chambers in a volume of 800 ml. HeLa-G12D cells were
induced with Doxycycline (Dox) 24h before seeding and kept in Dox for the rest of the experiment. The day after seeding, DMSO
or Poloppin (at the respective GI50 for cell killing: 10mM (HeLa) or 5mM (HeLa-KRASG12D) was added to thewells and live cell imaging
was performed using a fully motorised Leica DMI6000 B inverted microscope equipped with Evolve 512 EMCCD Camera with an
exposure time of 98ms. Bright field images were takenwith a HCX PL APO 40x/0.85 CORRCSDRY objective every 5min for duration
of 48h.
Pharmacokinetic Study
Mice were dosed orally with 10mg/kg Poloppin-II, and blood samples were taken from 3mice per time point, and frozen until all sam-
ples were available. Plasma was prepared from each sample and Poloppin-II levels analysed by a pre-established methodology
(UHPLC-TOF MS using electrospray ionisation).
Xenograft Study
Tumours were established by sub-cutaneous implantation of 2 x 106 HCT116 cells suspended in 50% Matrigel into the flanks of a
cohort of mice. When a sufficient number of mice had developed tumours of approximately 100mm3, they were randomly assigned
to three groups: Vehicle, 50mg/kg Poloppin-II or 200mg/kg Poloppin-II, with 10mice per group.Mice were treated orally according to
their treatment group once every three days. Tumour volume was measured three times per week with calipers. Body weight was
measured three times per week. In addition to mice assigned to tumour volume efficacy arm of the study, 16 mice with established
HCT116 xenografts were assigned to either Vehicle or 200mg/kg oral dosing groups, with 8 mice per group. 24 hours after a single
dose, mice were euthanised, tumours removed, snap frozen and 30-50microgram of lysates were analysed by Western blotting on
4-12% Bis-Tris acrylamide gels, and transferred using the Invitrogen iBlot dry system. Phospho-Histone H3 was detected using
Abcam antibody ab5176, beta-actin with Sigma antibody a5316. Secondary detection was achieved with the appropriate HRP-con-
jugated antibodies from Cell Signalling Technology. HRP was visualised with ECL-Plus (GE Healthcare).
SILAC and mass spectrometry Samples were processed for phosphoproteomic analysis as follows. In order to generate light, me-
dium and heavy stable isotope-labelled HeLa S3 cells, arginine and lysine free DMEM medium (Dundee Cell Products) was supple-
mented with 10% dialysed FBS (GIBCO), 200 mg/L L-proline and either L-lysine (Lys0) together with L-arginine (Arg0), L-lysine-2H4
(Lys4) with L-arginine-U-13C6 (Arg6) or L-lysine-U-
13C6-
15N2 (Lys8) with L-arginine-U-
13C6-
15N4 (Arg10) at final concentrations of
28 mg/L for the arginine and 146 mg/L for the lysine until fully metabolically labelled. For SILAC experiments, 2 x 15 cm dishes
per condition were treated with PLK inhibitors or DMSO and mitotic cells isolated by shake-off. To increase the yield for DMSO
treated control cells, media was replaced after initial shake-off and plates returned to the incubator. A second round of shake off
was performed after a further 1 hour incubation. Cells were washed in cold PBS, lysed in lysis buffer (100 mM Tris pH 7.6, 2%
SDS, 50 mM NaF, 1 x PhosStop [Roche], 1 x mammalian protease inhibitor [Sigma]), quantified and 1.67 mg of each lysate mixed
1:1:1 (Hammond et al., 2015; van den Biggelaar et al., 2014).
Filter-aided sample preparation (FASP) was used to trypsin digest and isolate peptides (Hammond et al., 2015; van den Biggelaar
et al., 2014). For proteome analysis, 5% of the material was removed after FASP. Phosphopeptides were fractionated from the
remaining 95% using strong cation exchange (Resource S, GE Healthcare), and enriched using TiO2 (van den Biggelaar et al.,
2014). All samples were cleaned up using C18 stage tips before analysis by LC-MS. Samples were analysed by the University of War-
wick Proteomics Research Technology Platform. Samples were fractionated by reversed phase chromatography using an Ultimate
3000 RSLCnano system (Dionex) coupled to a Thermo Orbitrap Fusion (Thermo Scientific). Samples were loaded onto an Acclaim
PepMap m-precolumn cartridge 300 mm i.d. x 5 mm, 5 mm, 100 A˚ for 8 min at 10 mL/min in 2% acetonitrile, 0.1% trifluoroacetic acid.
For proteome the peptides were then eluted onto an Acclaim PepMap RSLC 75 mm i.d. x 50 cm, 2 mm, 100 A˚ (Thermo Scientific) at
250 nL/min,using a 110 minute gradient of 8-25% acetonitrile in 0.1% formic acid followed by a 22 minute gradient from 25-35%
acetonitrile in 0.1% formic acid. For phosphopeptides sample was eluted from the precolumn at 300 nL/min onto an AcclaimPepMap
RSLC 75 mm x 25 cm, 2 mm, 100 A˚ (Thermo Scientific) using a 37 min gradient from 8-25% acetonitrile in 0.1% formic acid, then an
8min gradient from 25-35%acetonitrile in 0.1% formic acid. Eluting peptides were converted to gas-phase ions bymeans of electro-
spray ionization and analysed on a Thermo Orbitrap Fusion (Thermo Scientific). Survey scans of peptide precursors from 375 to
1500m/zwere performed at 240K resolution (at 200m/z) with a 2x105 or 4x105 ion count target for proteomes or phosphoproteomes,
respectively. Themaximum injection time was set to 150ms. TandemMSwas performed by isolation at 1.2 Th using the quadrupole,Cell Chemical Biology 24, 1017–1028.e1–e7, August 17, 2017 e5
HCD fragmentation with normalized collision energy of 30, and rapid scan MS analysis in the ion trap. The MS2 ion count target was
set to 3x103 or 104 for proteomes or phosphoproteomes, respectively. The maximum injection time was 200 ms. Precursors with
charge state 2–6 were selected and sampled for MS2. Dynamic exclusion duration was set to 60 s for proteomes or 50 s for phos-
phoproteomes, with a 10 ppm tolerance around the selected precursor and its isotopes. Monoisotopic precursor selection was
turned on. The instrument was run in top speed mode.
Resistance to PLK1 Inhibitors
HCT116wild-type cells (Horizon Discovery Ltd.) cultured inMcCoy’s 5A (Life Technologies #26600) medium supplemented with 10%
Foetal Calf Serum (Life Technologies #10270) were treated on three occasions with titrations of the PLK1ATP-competitive inhibitor BI
2536 (Selleckchem #S1109) or Poloppin in order to determine the 2.5xGI50, 3xGI50 and 5xGI50 values for each compound required to
initiate the development of resistance. Cells were subsequently treated with 2.5x GI50, 3x GI50 and 5x GI50 concentrations of either
compound, changing media and compound every three to four days until resistant colonies emerged or no viable cells remained.
Single cell clones were isolated from cells resistant to 5x GI50 BI 2536. Equivalent experiments using 3x GI50 or 2.5x GI50 doses
of Poloppin or BI2536 yielded identical results (data not shown). BI 2536-resistant clones (HCT116 BI 2536-Res. Clones) were
treated with BI2536 or Poloppin, alongside drug-sensitive parental HCT116 cells (HCT116 wt), and viability was assessed after
72 h. Viability is represented as percentage survival normalised to DMSO control. For PLK1 mutation analysis resistant clones
were enriched for mitotic cells by treatment for 16h with Nocodazole (SigmaM1404) prior to harvesting by scraping and RNA extrac-
tion using Qiagen RNeasy Mini Kits (Qiagen: 74104). cDNA was synthesized using Life Technologies First Strand Synthesis pro-
tocols with Superscript III (Life Technologies 18080044), RNase H digested (New England Biolabs M0297S) and subject to PCR
for the PLK1 following amplicon. Primers were designed to accommodate additional UTR cDNA in order for Nextera XT kits (Cam-
bridge Genomic Services, University Of Cambridge) to append tagging information without subsequent loss of sequence integrity, as
follows: PLK1F 5’-TTGTAACGTTCCCAGCGC, PLK1R 5’-GGCACACTGCAGACATGGC, PLK2F 5’-TGCTAGTCGGCACCAGAGG,
PLK2R 5’-TTCGTACCACCACATGTCCA, PLK3F 5’-CGCAGCGTAGCAAATCCAG, and PLK3R 5’-AAAGCTGGTCCCTGATTCCC
PCR reactions were carried out using Amplitaq Gold polymerase (Applied Biosystems N8080241) with a 25-cycle programme.
PCR products were gel-purified (Qiagen 28704) before being mixed in equimolar quantities in the case of each cell line and sub-
mitted for sequencing. Prepared samples were submitted for next generation sequencing using MiSeq Nano run with Nextera XT
library preparation. Sequencing and subsequent bioinformatics were performed by Cambridge Genomic Services (University Of
Cambridge).
RT-qPCR Assay
Total RNA from cultured cells was extracted using TRIzol reagent following the manufacturer instructions (Qiagen). Total RNA sam-
ples were submitted to Cambridge Genomic Services (CGS) for whole-transcript profiling on the Affymetrix Gene ST plate arrays and
subsequent bioinformatics analysis. For relative quantification of gene expression levels and microarray validation experiments,
equal amounts of cDNA were synthesized using SuperScript III Reverse Transcriptase kit (Invitrogen). qPCR was performed using
QuantiTect SYBR Green PCR Kit and cycling conditions used were 94C for 15 sec, 55C for 30 sec, and 70C for 30 sec for 40
cycles. The specificity of the reaction was verified by melt curve analysis. Experiments were performed using StepOne Real-
Time PCR Systems (Applied Biosystems). Primers used in this assay are: c-Met (QT00023408), PLK1 (QT00049749), PLK2
(QT00049406), PLK3 (QT00025207), PLK4 (QT00029967) and beta-actin (QT01680476) from Qiagen.
siRNA Sensitization
Cells were reverse-transfected with 50nM (SW48 parental, SW48 KRAS G12D and Panc-1) or 25nM (HeLa Flp-In T-REx parental
cells) siRNA using Dharmafect (GE Dharmacon) as manufacturer’s recommendations. Where transfected cells were subsequently
treated with compounds, the cells were allowed to settle overnight and then treated with compound at the indicated concentration
the following day. Viability was assessed after 72 hrs, with the SRB colorimetric assay. Knockdown efficiencies were determined
by Western blot or RT-qPCR. Oligos against the following target sequences were used. c-MET (Qiagen): AACACCCATCCAGAAT
GTCAT, AAGCCAATTTATCAGGAGGTG, AAGTATCAGCTTCCCAACTTC. PLK1 (Qiagen): CAACGGCAGCGTGCAGATCAA. PLK2
(SMARTpool; Dharmacon): ACACAGAAGGAGAACGAUA, CAUCAAUGAGGAUAGGAUA, CUGCCUAGUGUUACUGAUA, ACAAA
GUCUACGCCGCAAA. PLK3 (SMARTpool; Dharmacon): GCGAGAAGAUCCUAAAUGA, GCAAGUGGGUUGACUACUC, GCACAU
CCGUUGGCCAUCA, GACCUCAAGUUGGGAAAUU. PLK4 (Qiagen): AAGGACTTGGTCTTACAACTA.
QUANTIFICATION AND STATISTICAL ANALYSIS
For live cell imaging analysis image sequences were viewed using ImageJ software and cell fate was analysed manually. Time spent
in mitosis for different groups was compared with a Kruskal-Wallis test and Dunn’s multiple comparison correction.
For phosphoproteomics analysis rawMS peak lists were searched against the Uniprot database (downloaded July 2016) using the
Andromeda search engine and processed with the MaxQuant software suite (version 1.5.5.1).
Nanoluciferase enzyme activity of PLK1- or PLK4-Nanoluc fusion protein was analysed using GraphPad Prism. Data were normal-
ised as follows: (treatment A RLU value at XC temp/treatment A RLU value at 42C temp) x 100. Using the Boltzmann sigmoidal
equation, a curve was then fitted to the normalised data. From this non-linear fit, a V50 value was generated, which in this contexte6 Cell Chemical Biology 24, 1017–1028.e1–e7, August 17, 2017
represents the aggregation onset temperature (Tagg), at which 50% of the PLK1- or PLK4-Nanoluc fusion protein has aggregated.
Bliss model independence synergy was performed as follows: 96-well plates were treated with a dilution series of each drug in an
83 8 checkerboard pattern of combinations (Lin et al., 2012). After SRB staining to obtain the growth inhibition data, we used Com-
benefit software to identify synergistic drug combinations, focusing on BLISS independence (Di Veroli et al., 2016). The single-agent
inhibition values were used to calculate a drug combination surface under the assumption of an additive effect. Regions of synergy
were then detected by comparing obtained data from a combination with the calculated additive effect (derived by subtracting the
calculated additive inhibition values from the measured inhibition to obtain the final difference values). In the final synergy surface,
positive values hence indicate synergy regions, whereas negative difference values identify antagonistic effects.Cell Chemical Biology 24, 1017–1028.e1–e7, August 17, 2017 e7
